Cantor Fitzgerald Lifts Earnings Estimates for Biohaven

Key Points

• Cantor Fitzgerald has increased its FY2025 earnings estimate for Biohaven Ltd. to ($7.44) per share, slightly up from the previous estimate of ($7.54), maintaining a "Strong-Buy" rating on the stock.
• Biohaven's current consensus estimate for full-year earnings stands at ($8.90) per share, with projections for FY2026 set at ($4.67) per share.
• Despite recent changes in target prices from various research analysts, Biohaven has an average price target of $53.75 and a consensus rating of "Buy" from market analysts.

Biohaven Ltd. (NYSE:BHVN - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Biohaven in a research report issued on Wednesday, August 13th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($7.44) per share for the year, up from their previous estimate of ($7.54). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share. Cantor Fitzgerald also issued estimates for Biohaven's FY2026 earnings at ($4.67) EPS.

BHVN has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective (down previously from $54.00) on shares of Biohaven in a research note on Tuesday, August 12th. Robert W. Baird cut their target price on Biohaven from $57.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. William Blair upgraded Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partners lowered their price objective on Biohaven from $60.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Finally, Morgan Stanley cut their price objective on Biohaven from $63.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $53.75.

Biohaven Trading Up 2.0%

NYSE BHVN traded up $0.31 on Friday, hitting $16.02. The company's stock had a trading volume of 1,875,918 shares, compared to its average volume of 2,083,011. The company's 50-day moving average is $14.48 and its 200 day moving average is $21.55. The firm has a market cap of $1.69 billion, a PE ratio of -2.09 and a beta of 0.98. Biohaven has a 1-year low of $12.79 and a 1-year high of $55.70. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 1.91.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($1.94) EPS for the quarter, hitting the consensus estimate of ($1.94).

Institutional Investors Weigh In On Biohaven

Several institutional investors and hedge funds have recently made changes to their positions in BHVN. SVB Wealth LLC acquired a new position in Biohaven in the first quarter valued at approximately $25,000. Parallel Advisors LLC increased its stake in shares of Biohaven by 319.8% in the 1st quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock valued at $33,000 after acquiring an additional 1,036 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Biohaven by 53.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company's stock valued at $43,000 after acquiring an additional 623 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Biohaven by 84,800.0% during the 1st quarter. IFP Advisors Inc now owns 2,547 shares of the company's stock valued at $61,000 after acquiring an additional 2,544 shares during the period. Finally, Elkhorn Partners Limited Partnership boosted its stake in Biohaven by 26.1% during the second quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company's stock worth $82,000 after acquiring an additional 1,200 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.